CellCarta is a global contract research organization providing testing services including biomarker solutions, immune monitoring, proteomics, genomics, histopathology, and regulatory expertise. This description is self-described as the company offers advanced scientific capabilities to support therapeutic development.

CellCarta

Cognate BioServices is a contract development and manufacturing organization specializing in cell and gene-mediated cell therapy. The company has supported the development of FDA-approved therapies and conducted numerous studies in this field.

Cognate BioServices

CellCarta | 24,476 followers on LinkedIn. As a global leader in precision medicine testing services, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials. 

CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as digital pathology/AI and sample management, logistics and kitting services.

Mark Watson

Senior Financial Analyst

Anna-Maria Leoci

Co-founder and Vice-Chairman at CellCarta

Martin LeBlanc

Christopher Ung

⭐ Live from #SITC2024 ! Catch Elizabeth Ross and Mark Kockx presenting poster #126 on developing a visual scoring method to determine inflamed, excluded or desert immune phenotype in NSCLC, colorectal, and urothelial cancers. Missed yesterday’s posters. No worries, Damien Montamat-Sicotte and Jean-Philippe Goulet are still at Booth 1310, ready to chat about cytometry analysis (#833) and advanced CITE-seq data (#163). Stop by to connect. #PrecisionMedicine #Immunooncology #Biomarkers

Think you’ve got what it takes to top the leaderboard? 🎮 Swing by Booth #1310 and prove it! Ready, set, game on! 💥 See you there!

Hello from the team at #SITC2024 ! 👋 We’d love to chat about your latest scientific challenges and how we can support your immunotherapy research. Drop by Booth 1310 or book a meeting here 👇 https://bit.ly/3HQzLHL See you there!

Can you clear the competition at #SITC2024 ? Put your gaming skills to the test, visit Booth 1310! 🕹️

Today is #InternationalPathologyDay ! 🔬 Let’s take a moment to recognize the skilled pathologists working tirelessly to guide treatments, and advance research. At CellCarta, we really don’t know where we’d be without our own talented team of pathologists. Meet the team here 👉 https://lnkd.in/g-sQqaT8

#SITC2024 is starting tomorrow! Don’t miss our three posters: ⭐ Abstract 126: Development of a visual scoring method to determine inflamed, excluded or desert immune phenotype in non-small cell lung cancer, colorectal cancer, and urothelial cancer ⭐ Abstract 833: Accelerating analysis of cytometry data sets leveraging a visualization tool built within CellEngine, a cloud-based cytometry analysis software ⭐ Abstract 163: Analyzing CITE-seq data like an immunologist with a hybrid hierarchical gating approach in CellEngine software Stop by the posters and book a meeting with our team to find out more! https://bit.ly/3HQzLHL #PrecisionMedicine #Immunooncology #Biomarkers Show Less

Did you know CellCarta offers kitting solutions to facilitate the logistics of PK and biomarker samples during clinical trials? Our team of experts collaborates with you to ensure kits are tailored to your needs. Check out our services: https://bit.ly/3YRjyJN #CellCarta #CROLaboratory #Precisionmedicine

Our Naperville laboratory is upgrading its genomic capabilities with the NovaSeq X Plus sequencing instrument. This exciting development means we are now able to provide our customers with: ✔️Faster sequencing times ✔️Increased throughout ✔️Improved cost efficiency We are delighted to bring these benefits to you, and to continue to utilize the latest innovations in sequencing to support your research. Learn more: https://bit.ly/3URAuzt #Genomics #PrecisionMedicine #PCR #CellCarta

PBMC processing following robust, standardized SOPs to ensure quality data. Sounds interesting? https://bit.ly/4foNlll Our state-of-the-art facility in Naperville, U.S. offers PBMC processing and delivers: ⭐ Fast turn arounds to support short stability windows, with samples collected, shipped and processed within 24hrs ⭐ Capabilities with both Ficoll and CPT tubes that lead to >90% cell viability ⭐ Onsite biorepository services Discover why we’re the CRO partner of choice for PBMC processing, but also sample logistics the world over. 🌏 https://bit.ly/4cSIvuL #CellCarta #PrecisionMedicine #CellTherapy

Unsure how to transition your clinical trial assay to companion diagnostic (CDx)? Our experts can help. Learn more here 👉 https://bit.ly/3qALZ2d #CellCarta #ClinicalTrials #PrecisionMedicine

Metric
Company Name	CellCarta	Cognate BioServices
Symbol
MSH ID	COM:CELLCARTA	COM:COGNATEBIOSERVICES
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Healthcare & Health Services
Industry	Contract Research Organization	Biotechnology
Country	US	US
Stage		Series B
Employee Count
Website	cellcarta.com	cognatebioservices.com
LinkedIn	cellcarta	cognate-bioservices
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CELL

COM:CELLCARTA

CellCarta

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue